NCT06738719

A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients With Moderately to Severely Active Rheumatoid Arthritis

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 192 (actual)
• Sponsor: Celltrion · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis

Conditions

• Moderately to Severely Active Rheumatoid Arthritis

Interventions

Type	Name	Description
BIOLOGICAL	CT-P13 SC Auto-Injector	Subcutaneous(SC) Injection
BIOLOGICAL	Placebo Auto-Injector	Subcutaneous(SC) Injection

Timeline

• Start date: 2025-01-03
• Primary completion: 2025-06-25
• Completion: 2026-04-15
• First posted: 2024-12-18
• Last updated: 2025-07-04

Locations

1 site across 1 country: Poland

Regulatory

• FDA-regulated drug study